Targeted drug combo shows promise against melanoma

CHICAGO - The combination of two experimental pills developed by GlaxoSmithKline Plc has shown promise as a treatment for melanoma, the most deadly type of skin cancer, according to new research.
The early stage trial involved patients with advanced melanoma with a specific genetic mutation who were treated with drugs designed to block MEK (GSK212) and BRAF (GSK436), two components of the same pathway used by the cancer to drive tumor growth.
Subscribe for our daily newsletter
Subscribe for our daily newsletter

By subscribing I accept the terms of use and privacy policy